Payment overview · 2025
General Payments
$117.58
5 reported records · 2 companies
Healthcare provider profile · identity verified
Frederick Joseph Reed, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DAVENPORT, WA · NPI 1467411157
Verified facts
What the public records show
CMS Open Payments records show Frederick Joseph Reed, M.D. received $117.58 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 63.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.48 | 63.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.10 | 36.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.58 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.10 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 278 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 235 | 69 |
| Lisinopril | Lisinopril | 224 | 66 |
| Losartan Potassium | Losartan Potassium | 196 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 188 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 43 |
| Omeprazole | Omeprazole | 177 | 54 |
| Gabapentin | Gabapentin | 138 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 131 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 129 | 40 |
| Ozempic | Semaglutide | 124 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 120 | 13 |
| Tramadol Hcl | Tramadol Hcl | 108 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 32 |
| Metformin Hcl Er | Metformin Hcl | 91 | 29 |
| Metformin Hcl | Metformin Hcl | 90 | 32 |
| Alprazolam | Alprazolam | 89 | 16 |
| Potassium Chloride | Potassium Chloride | 88 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 18 |
| Simvastatin | Simvastatin | 79 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 77 | suppressed |
| Famotidine | Famotidine | 66 | 24 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Xarelto | Rivaroxaban | 64 | 11 |
| Furosemide | Furosemide | 63 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 16 |
| Prednisone | Prednisone | 55 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 14 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 49 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Allopurinol | Allopurinol | 42 | 12 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 13 |
| Eliquis | Apixaban | 40 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Azithromycin | Azithromycin | 28 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | 24 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Triazolam | Triazolam | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.58 · 5 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error